Opinions
Glenn Paradis, BA, CFA
Axcan Pharmaceuticals
AXP-T
DON'T BUY
May 20, 2003
Its OK earnings wise. They are trying to make a hostile take over which looks expensive. Core business is OK.
$16.930
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet.
biotechnology
pharmaceutical
Advertising